Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Urology. 2011 Sep;78(3):722.e1-722.e6. doi: 10.1016/j.urology.2011.04.044. Epub 2011 Jul 13.
To develop a novel protein-anchor technology to immobilize human interleukin-2 on tumor cells to induce antitumor immunity.
Interleukin-2 surface-modified MB49 cells were prepared as a vaccine. Subcutaneous and pulmonary metastatic mouse models of MB49 bladder cancer were used to evaluate the antitumor efficiency of the vaccine. Immunohistochemistry, flow cytometric, and cytotoxic T-lymphocyte assay were performed to assess the proportion and cytotoxicity of the T lymphocytes.
The IL-2 surface-modified MB49 cell vaccine inhibited tumor growth and extended the survival of the mice, and the vaccine-cured mice effectively resisted the second MB49 but not the RM-1 prostate cancer cell challenge. Furthermore, more cytotoxicity on the MB49 cells and more CD4-positive, CD8-positive T cells appeared in the vaccine-treated group.
The results of our study have demonstrated that the human interleukin-2 surface-modified MB49 bladder cancer cell vaccine induced specific antitumor immunity and was efficient against metastatic bladder cancer.
开发一种新型的蛋白锚定技术，将人白细胞介素-2固定在肿瘤细胞上，诱导抗肿瘤免疫。
将白细胞介素-2表面修饰的 MB49 细胞制备成疫苗。采用 MB49 膀胱癌皮下和肺转移小鼠模型评估疫苗的抗肿瘤效率。通过免疫组织化学、流式细胞术和细胞毒性 T 淋巴细胞试验评估 T 淋巴细胞的比例和细胞毒性。
IL-2 表面修饰的 MB49 细胞疫苗抑制肿瘤生长并延长了小鼠的生存时间，且疫苗治愈的小鼠能有效抵抗第二次 MB49 但不能抵抗 RM-1 前列腺癌细胞的攻击。此外，在疫苗治疗组中，MB49 细胞的细胞毒性和 CD4 阳性、CD8 阳性 T 细胞的比例均有所增加。
我们的研究结果表明，人白细胞介素-2 表面修饰的 MB49 膀胱癌细胞疫苗诱导了特异性抗肿瘤免疫，对转移性膀胱癌具有高效性。
